Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Camrelizumab + Apatinib in Multiple Primary Lung Cancer
NCT06607770Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in multiple primary lung cancer (MPLC). Started Sep 2024; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
multiple primary lung cancer (MPLC)
Beyond the preview
Go deeper on NCT06607770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607770.